really .04 should be the base for this stock. at that sort of...

really .04 should be the base for this stock. at that sort of market cap its really only saying we are here and ready to go. the technology and IP aloe is worth $50 to a big pharma keen to bolt on a product line. when the sales start to flow in the coming quarters there is going to be a ready recognition that this business plan has resmed qualities. recurring revenue also. unique technology serving an unmet clinical need. why oh why has it taken so long for management to sell the story? if those .07 ops dont make it over the line that is a disgrace. easy money if they can get the thing to fair value.